Condition
Involutional Osteoporosis
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (3)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02063854Phase 2CompletedPrimary
A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets
NCT00212719Phase 3CompletedPrimary
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
NCT00212667Phase 3CompletedPrimary
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
NCT00212628Phase 3CompletedPrimary
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
Showing all 4 trials